Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.
Chen J, Bearz A, Kim DW, Mamdani H, Bauman J, Chiari R, Ou SI, Solomon BJ, Soo RA, Felip E, Shaw AT, Thurm H, Clancy JS, Lee K, O'Gorman M, Tanski C, Pithavala YK. Chen J, et al. Among authors: thurm h. Clin Pharmacokinet. 2024 Feb;63(2):171-182. doi: 10.1007/s40262-023-01309-4. Epub 2023 Dec 11. Clin Pharmacokinet. 2024. PMID: 38079095 Free PMC article.
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
Bearz A, Martini JF, Jassem J, Kim SW, Chang GC, Shaw AT, Shepard DA, Dall'O' E, Polli A, Thurm H, Zalcman G, Garcia Campelo MR, Penkov K, Hayashi H, Solomon BJ. Bearz A, et al. Among authors: thurm h. J Thorac Oncol. 2023 Nov;18(11):1581-1593. doi: 10.1016/j.jtho.2023.07.023. Epub 2023 Aug 3. J Thorac Oncol. 2023. PMID: 37541389 Free article.
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP. Goldsmith KC, et al. Among authors: thurm hc. Nat Med. 2023 May;29(5):1092-1102. doi: 10.1038/s41591-023-02297-5. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012551 Free PMC article. Clinical Trial.
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
Mazieres J, Iadeluca L, Shaw AT, Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Kim DW, Mok T, Reisman A, Thurm H, Polli AM, Liu G. Mazieres J, et al. Among authors: thurm h. Lung Cancer. 2022 Dec;174:146-156. doi: 10.1016/j.lungcan.2022.11.004. Epub 2022 Nov 7. Lung Cancer. 2022. PMID: 36410210 Free article. Clinical Trial.
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
Dagogo-Jack I, Abbattista A, Murphy JF, Krulewicz S, Do A, Peterson J, Lin JJ, Gainor JF, Messina R, Krueger EA, Thurm H, Yeap BY. Dagogo-Jack I, et al. Among authors: thurm h. J Thorac Oncol. 2023 Jan;18(1):67-78. doi: 10.1016/j.jtho.2022.09.219. Epub 2022 Sep 29. J Thorac Oncol. 2023. PMID: 36184067 Free article.
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
Solomon BJ, Bauer TM, Ignatius Ou SH, Liu G, Hayashi H, Bearz A, Penkov K, Wu YL, Arrieta O, Jassem J, Calella AM, Peltz G, Polli A, Thurm H, Mok T. Solomon BJ, et al. Among authors: thurm h. J Clin Oncol. 2022 Nov 1;40(31):3593-3602. doi: 10.1200/JCO.21.02278. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605188 Free PMC article. Clinical Trial.
Response to "Lorlatinib Exposed: A Far from Optimal Dose".
Chen J, Ruiz-Garcia A, James LP, Peltz G, Thurm H, Clancy J, Hibma J. Chen J, et al. Among authors: thurm h. Clin Pharmacol Ther. 2022 Jun;111(6):1197-1198. doi: 10.1002/cpt.2580. Epub 2022 Mar 31. Clin Pharmacol Ther. 2022. PMID: 35358326 No abstract available.
27 results